# A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

> **NCT01310816** · PHASE2 · COMPLETED · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 105 (actual)

## Conditions studied

- Conventional Chondrosarcoma

## Interventions

- **DRUG:** IPI-926
- **DRUG:** Placebo Arm

## Key facts

- **NCT ID:** NCT01310816
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-11
- **Final completion:** 2013-12
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2013-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01310816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01310816, "A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01310816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*